Generalized Anxiety and Seroquel
Information source: Mclean Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Generalized Anxiety Disorder; Seroquel XR
Intervention: Seroquel XR (Drug)
Phase: N/A
Status: Terminated
Sponsored by: Mclean Hospital
Summary
The 12 week clinical trial of Seroquel in Generalized Anxiety Disorder (GAD) patients will
be combined with fMRI experiments.
Clinical Details
Official title: Pharmacotherapy of Generalized Anxiety Disorder With Seroquel: Normalization of Brain Stress and Reward Function
Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: The primary outcome will be the change from baseline in GAD symptomatology at the Week 12 timepoint.Change from baseline GAD symptomatology at the Week 12 timepoint.
Detailed description:
Subjects will be recruited from clinic patients and known research subjects at McLean
Hospital, as well as by advertisements in the media, flyers, and word of mouth. An initial
telephone interview will be conducted to determine if potential subjects meet the basic
study requirements. Subjects will be also screened for drug use. If no obvious health
problems are present, subjects will be scheduled for an evaluation. Upon arrival at the
research unit, each subject will first complete a standardized interview schedule designed
to obtain personal and background data such as age, marital status, socio-economic status,
education, employment, etc. The Research Assistant will give subjects both verbal and
written descriptions of the study procedures. After briefing subjects on the reasons for the
research, subjects will be given the opportunity to ask questions. When they are ready,
subjects will be asked to sign the written informed consent form approved by the Mclean
Institutional Review Board (IRB). Functional magnetic resonance imaging scans to examine
brain functioning will be obtained from GAD patients (N=30) at baseline and after 12 weeks.
Seroquel XR tablets will be flexibly dosed and begun at a target dose of 50 mg on day 1, 100
mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal daily dose of 400 mg on
subsequent days.
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Provision of written informed consent
- Fluency in English
- A diagnosis of GAD
- No pregnancy
- Right-handedness
- Psychotropic medication-free at the start of the study
Exclusion Criteria:
- Pregnancy or lactation
- Any current DSM-IV-TR Axis I disorder
- Any mental retardation or cognitive impairment that precludes informed consent
- Known intolerance or lack of response to quetiapine fumarate
- Substance or alcohol dependence at enrollment
- Participation in another drug trial within 4 weeks prior enrollment
- History of allergic reaction or hypersensitivity to Seroquel or Seroquel XR
- History of prior Seroquel or other antipsychotic agents use
- Contraindications to magnetic resonance imaging
- Treatment with an effective medication for GAD
Locations and Contacts
McLean Hospital, Belmont, Massachusetts 02478, United States
Additional Information
Starting date: February 2010
Last updated: October 24, 2013
|